Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QuantRx Biomedical, a broad-based diagnostic company, has announced that the US Patent and Trademark Office has issued a new patent expanding the company's oral testing intellectual property suite.
Subscribe to our email newsletter
According to QuantRx, this new patent for oral testing devices expands the company’s protection, and will allow it to bring its ultrasensitive RapidSense technology to address the point-of-care market opportunity, in particular the oral drug-of-abuse (DOA) market.
William Fleming, president of diagnostics at QuantRx, said: “This new technology provides the company with the ability to provide true one step CLIA waived point-of-care DOA tests that will meet the Substance Abuse and Mental Health Services Administration (SAMSA) guidelines for the first time.
“RapidSense with its exceptional low level sensitivity, coupled with our device technology is well on its way to entering the market and capitalizing on the point-of-care testing markets and we believe these markets offer near-term opportunities for QuantRx.”